Drugs / SB3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05530057 | Feb 2020 → Jun 2028 expected | breast cancer | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02149524 | Apr 2014 → Mar 2016 | HER2 positive breast carcinoma | Samsung Bioepis Co., Ltd. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB3 | “Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.” NCT05530057 ↗ |
| Route | Intravenous | “SB3 8 mg/kg I.V. over 90 minutes” NCT05530057 ↗ |